Scalper1 News
Biotech Bluebird Bio (BLUE) got multiple price-target increases Monday in the wake of new data on its cell therapy released over the weekend, and also announced a new chief scientific officer. Bluebird Bio stock, however, was down a fraction in afternoon trading Monday amid a larger market selloff. BMO Capital Markets and Bank of America both hiked their price targets to near 240 in light of Bluebird’s report over the weekend that a patient with Scalper1 News
Scalper1 News